1
PV 6241 AMP
ZYPREXA®
Olanzapine Tablets
ZYPREXA® ZYDIS®
Olanzapine Orally Disintegrating Tablets
ZYPREXA® IntraMuscular
Olanzapine for Injection
WARNING
Increased Mortality in Elderly Patients with Dementia-Related Psychosis — Elderly
patients with dementia-related psychosis treated with antipsychotic drugs are at an
increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of
10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death
in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated
patients. Over the course of a typical 10-week controlled trial, the rate of death in
drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo
group. Although the causes of death were varied, most of the deaths appeared to be either
cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with
conventional antipsychotic drugs may increase mortality. The extent to which the findings
of increased mortality in observational studies may be attributed to the antipsychotic drug
as opposed to some characteristic(s) of the patients is not clear. ZYPREXA (olanzapine) is
not approved for the treatment of patients with dementia-related psychosis (see
WARNINGS).
DESCRIPTION
ZYPREXA (olanzapine) is a psychotropic agent that belongs to the thienobenzodiazepine
class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b]
[1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresponds to a molecular
weight of 312.44. The chemical structure is:
Olanzapine is a yellow crystalline solid, which is practically insoluble in water.
ZYPREXA tablets are intended for oral administration only.
Each tablet contains olanzapine equivalent to 2.5 mg (8 µmol), 5 mg (16 µmol), 7.5 mg
(24 µmol), 10 mg (32 µmol), 15 mg (48 µmol), or 20 mg (64 µmol). Inactive ingredients are
carnauba wax, crospovidone, hydroxypropyl cellulose, hypromellose, lactose, magnesium
2
stearate, microcrystalline cellulose, and other inactive ingredients. The color coating contains
Titanium Dioxide (all strengths), FD&C Blue No. 2 Aluminum Lake (15 mg), or Synthetic Red
Iron Oxide (20 mg). The 2.5, 5, 7.5, and 10 mg tablets are imprinted with edible ink which
contains FD&C Blue No. 2 Aluminum Lake.
ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) is intended for oral administration
only.
Each orally disintegrating tablet contains olanzapine equivalent to 5 mg (16 µmol), 10 mg
(32 µmol), 15 mg (48 µmol) or 20 mg (64 µmol). It begins disintegrating in the mouth within
seconds, allowing its contents to be subsequently swallowed with or without liquid.
ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) also contains the following inactive
ingredients: gelatin, mannitol, aspartame, sodium methyl paraben and sodium propyl paraben.
ZYPREXA IntraMuscular (olanzapine for injection) is intended for intramuscular use only.
Each vial provides for the administration of 10 mg (32 µmol) olanzapine with inactive
ingredients 50 mg lactose monohydrate and 3.5 mg tartaric acid. Hydrochloric acid and/or
sodium hydroxide may have been added during manufacturing to adjust pH.
CLINICAL PHARMACOLOGY
Pharmacodynamics
Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following
receptors: serotonin 5HT2A/2C, 5HT6, (Ki=4, 11, and 5 nM, respectively), dopamine D1-4
(Ki=11-31 nM), histamine H1 (Ki=7 nM), and adrenergic α1 receptors (Ki=19 nM). Olanzapine is
an antagonist with moderate affinity binding for serotonin 5HT3 (Ki=57 nM) and muscarinic M1-5
(Ki=73, 96, 132, 32, and 48 nM, respectively). Olanzapine binds weakly to GABAA, BZD, and
β adrenergic receptors (Ki>10 µM).
The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia,
is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated
through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of
action of olanzapine in the treatment of acute manic episodes associated with Bipolar I Disorder
is unknown.
Antagonism at receptors other than dopamine and 5HT2 may explain some of the other
therapeutic and side effects of olanzapine. Olanzapine’s antagonism of muscarinic M1-5 receptors
may explain its anticholinergic-like effects. Olanzapine’s antagonism of histamine H1 receptors
may explain the somnolence observed with this drug. Olanzapine’s antagonism of adrenergic α1
receptors may explain the orthostatic hypotension observed with this drug.
Pharmacokinetics
Oral Administration
Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours
following an oral dose. It is eliminated extensively by first pass metabolism, with approximately
40% of the dose metabolized before reaching the systemic circulation. Food does not affect the
rate or extent of olanzapine absorption. Pharmacokinetic studies showed that ZYPREXA tablets
and ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) dosage forms of olanzapine are
bioequivalent.
Olanzapine displays linear kinetics over the clinical dosing range. Its half-life ranges from
21 to 54 hours (5th to 95th percentile; mean of 30 hr), and apparent plasma clearance ranges
from 12 to 47 L/hr (5th to 95th percentile; mean of 25 L/hr).
3
Administration of olanzapine once daily leads to steady-state concentrations in about one week
that are approximately twice the concentrations after single doses. Plasma concentrations,
half-life, and clearance of olanzapine may vary between individuals on the basis of smoking
status, gender, and age (see Special Populations).
Olanzapine is extensively distributed throughout the body, with a volume of distribution of
approximately 1000 L. It is 93% bound to plasma proteins over the concentration range of 7 to
1100 ng/mL, binding primarily to albumin and α1-acid glycoprotein.
Metabolism and Elimination — Following a single oral dose of 14C labeled olanzapine, 7% of
the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine
is highly metabolized. Approximately 57% and 30% of the dose was recovered in the urine and
feces, respectively. In the plasma, olanzapine accounted for only 12% of the AUC for total
radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major
circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the
concentration of olanzapine, and 4´-N-desmethyl olanzapine, present at steady state at 31% of
the concentration of olanzapine. Both metabolites lack pharmacological activity at the
concentrations observed.
Direct glucuronidation and cytochrome P450 (CYP) mediated oxidation are the primary
metabolic pathways for olanzapine. In vitro studies suggest that CYPs 1A2 and 2D6, and the
flavin-containing monooxygenase system are involved in olanzapine oxidation.
CYP2D6 mediated oxidation appears to be a minor metabolic pathway in vivo, because the
clearance of olanzapine is not reduced in subjects who are deficient in this enzyme.
Intramuscular Administration
ZYPREXA IntraMuscular results in rapid absorption with peak plasma concentrations
occurring within 15 to 45 minutes. Based upon a pharmacokinetic study in healthy volunteers, a
5 mg dose of intramuscular olanzapine for injection produces, on average, a maximum plasma
concentration approximately 5 times higher than the maximum plasma concentration produced
by a 5 mg dose of oral olanzapine. Area under the curve achieved after an intramuscular dose is
similar to that achieved after oral administration of the same dose. The half-life observed after
intramuscular administration is similar to that observed after oral dosing. The pharmacokinetics
are linear over the clinical dosing range. Metabolic profiles after intramuscular administration
are qualitatively similar to metabolic profiles after oral administration.
Special Populations
Renal Impairment — Because olanzapine is highly metabolized before excretion and only
7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact
on the pharmacokinetics of olanzapine. The pharmacokinetic characteristics of olanzapine were
similar in patients with severe renal impairment and normal subjects, indicating that dosage
adjustment based upon the degree of renal impairment is not required. In addition, olanzapine is
not removed by dialysis. The effect of renal impairment on metabolite elimination has not been
studied.
Hepatic Impairment — Although the presence of hepatic impairment may be expected to
reduce the clearance of olanzapine, a study of the effect of impaired liver function in
subjects (n=6) with clinically significant (Childs Pugh Classification A and B) cirrhosis revealed
little effect on the pharmacokinetics of olanzapine.
Age — In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine
was about 1.5 times greater in elderly (>65 years) than in non-elderly subjects (≤65 years).
Caution should be used in dosing the elderly, especially if there are other factors that might
4
additively influence drug metabolism and/or pharmacodynamic sensitivity (see DOSAGE AND
ADMINISTRATION).
Gender — Clearance of olanzapine is approximately 30% lower in women than in men. There
were, however, no apparent differences between men and women in effectiveness or adverse
effects. Dosage modifications based on gender should not be needed.
Smoking Status — Olanzapine clearance is about 40% higher in smokers than in nonsmokers,
although dosage modifications are not routinely recommended.
Race — In vivo studies have shown that exposures are similar among Japanese, Chinese and
Caucasians, especially after normalization for body weight differences. Dosage modifications for
race are, therefore, not recommended.
Combined Effects — The combined effects of age, smoking, and gender could lead to
substantial pharmacokinetic differences in populations. The clearance in young smoking males,
for example, may be 3 times higher than that in elderly nonsmoking females. Dosing
modification may be necessary in patients who exhibit a combination of factors that may result
in slower metabolism of olanzapine (see DOSAGE AND ADMINISTRATION).
For specific information about the pharmacology of lithium or valproate, refer to the
CLINICAL PHARMACOLOGY section of the package inserts for these other products.
CLINICAL EFFICACY DATA
Schizophrenia
The efficacy of oral olanzapine in the treatment of schizophrenia was established in
2 short-term (6-week) controlled trials of inpatients who met DSM III-R criteria for
schizophrenia. A single haloperidol arm was included as a comparative treatment in one of the
two trials, but this trial did not compare these two drugs on the full range of clinically relevant
doses for both.
Several instruments were used for assessing psychiatric signs and symptoms in these studies,
among them the Brief Psychiatric Rating Scale (BPRS), a multi-item inventory of general
psychopathology traditionally used to evaluate the effects of drug treatment in schizophrenia.
The BPRS psychosis cluster (conceptual disorganization, hallucinatory behavior, suspiciousness,
and unusual thought content) is considered a particularly useful subset for assessing actively
psychotic schizophrenic patients. A second traditional assessment, the Clinical Global
Impression (CGI), reflects the impression of a skilled observer, fully familiar with the
manifestations of schizophrenia, about the overall clinical state of the patient. In addition,
two more recently developed scales were employed; these included the 30-item Positive and
Negative Symptoms Scale (PANSS), in which are embedded the 18 items of the BPRS, and the
Scale for Assessing Negative Symptoms (SANS). The trial summaries below focus on the
following outcomes: PANSS total and/or BPRS total; BPRS psychosis cluster; PANSS negative
subscale or SANS; and CGI Severity. The results of the trials follow:
(1) In a 6-week, placebo-controlled trial (n=149) involving two fixed olanzapine doses of 1 and
10 mg/day (once daily schedule), olanzapine, at 10 mg/day (but not at 1 mg/day), was superior to
placebo on the PANSS total score (also on the extracted BPRS total), on the BPRS psychosis
cluster, on the PANSS Negative subscale, and on CGI Severity.
(2) In a 6-week, placebo-controlled trial (n=253) involving 3 fixed dose ranges of olanzapine
(5 ± 2.5 mg/day, 10 ± 2.5 mg/day, and 15 ± 2.5 mg/day) on a once daily schedule, the
two highest olanzapine dose groups (actual mean doses of 12 and 16 mg/day, respectively) were
superior to placebo on BPRS total score, BPRS psychosis cluster, and CGI severity score; the
5
highest olanzapine dose group was superior to placebo on the SANS. There was no clear
advantage for the high dose group over the medium dose group.
Examination of population subsets (race and gender) did not reveal any differential
responsiveness on the basis of these subgroupings.
In a longer-term trial, adult outpatients (n=326) who predominantly met DSM-IV criteria for
schizophrenia and who remained stable on olanzapine during open label treatment for at least
8 weeks were randomized to continuation on their current olanzapine doses (ranging from 10 to
20 mg/day) or to placebo. The follow-up period to observe patients for relapse, defined in terms
of increases in BPRS positive symptoms or hospitalization, was planned for 12 months, however,
criteria were met for stopping the trial early due to an excess of placebo relapses compared to
olanzapine relapses, and olanzapine was superior to placebo on time to relapse, the primary
outcome for this study. Thus, olanzapine was more effective than placebo at maintaining efficacy
in patients stabilized for approximately 8 weeks and followed for an observation period of up to
8 months.
Bipolar Disorder
Monotherapy — The efficacy of oral olanzapine in the treatment of acute manic or mixed
episodes was established in 2 short-term (one 3-week and one 4-week) placebo-controlled trials
in patients who met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes.
These trials included patients with or without psychotic features and with or without a
rapid-cycling course.
The primary rating instrument used for assessing manic symptoms in these trials was the
Young Mania Rating Scale (Y-MRS), an 11-item clinician-rated scale traditionally used to assess
the degree of manic symptomatology (irritability, disruptive/aggressive behavior, sleep, elevated
mood, speech, increased activity, sexual interest, language/thought disorder, thought content,
appearance, and insight) in a range from 0 (no manic features) to 60 (maximum score). The
primary outcome in these trials was change from baseline in the Y-MRS total score. The results
of the trials follow:
(1) In one 3-week placebo-controlled trial (n=67) which involved a dose range of olanzapine
(5-20 mg/day, once daily, starting at 10 mg/day), olanzapine was superior to placebo in the
reduction of Y-MRS total score. In an identically designed trial conducted simultaneously with
the first trial, olanzapine demonstrated a similar treatment difference, but possibly due to sample
size and site variability, was not shown to be superior to placebo on this outcome.
(2) In a 4-week placebo-controlled trial (n=115) which involved a dose range of olanzapine
(5-20 mg/day, once daily, starting at 15 mg/day), olanzapine was superior to placebo in the
reduction of Y-MRS total score.
(3) In another trial, 361 patients meeting DSM-IV criteria for a manic or mixed episode of
bipolar disorder who had responded during an initial open-label treatment phase for about two
weeks, on average, to olanzapine 5 to 20 mg/day were randomized to either continuation of
olanzapine at their same dose (n=225) or to placebo (n=136), for observation of relapse.
Approximately 50% of the patients had discontinued from the olanzapine group by day 59 and
50% of the placebo group had discontinued by day 23 of double-blind treatment. Response
during the open-label phase was defined by having a decrease of the Y-MRS total score to ≤12
and HAM-D 21 to ≤8. Relapse during the double-blind phase was defined as an increase of the
Y-MRS or HAM-D 21 total score to ≥15, or being hospitalized for either mania or depression. In
the randomized phase, patients receiving continued olanzapine experienced a significantly longer
time to relapse.
6
Combination Therapy — The efficacy of oral olanzapine with concomitant lithium or valproate
in the treatment of acute manic episodes was established in two controlled trials in patients who
met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. These trials
included patients with or without psychotic features and with or without a rapid-cycling course.
The results of the trials follow:
(1) In one 6-week placebo-controlled combination trial, 175 outpatients on lithium or valproate
therapy with inadequately controlled manic or mixed symptoms (Y-MRS ≥16) were randomized
to receive either olanzapine or placebo, in combination with their original therapy. Olanzapine
(in a dose range of 5-20 mg/day, once daily, starting at 10 mg/day) combined with lithium or
valproate (in a therapeutic range of 0.6 mEq/L to 1.2 mEq/L or 50 µg/mL to 125 µg/mL,
respectively) was superior to lithium or valproate alone in the reduction of Y-MRS total score.
(2) In a second 6-week placebo-controlled combination trial, 169 outpatients on lithium or
valproate therapy with inadequately controlled manic or mixed symptoms (Y-MRS ≥16) were
randomized to receive either olanzapine or placebo, in combination with their original therapy.
Olanzapine (in a dose range of 5-20 mg/day, once daily, starting at 10 mg/day) combined with
lithium or valproate (in a therapeutic range of 0.6 mEq/L to 1.2 mEq/L or 50 µg/mL to
125 µg/mL, respectively) was superior to lithium or valproate alone in the reduction of Y-MRS
total score.
Agitation Associated with Schizophrenia and Bipolar I Mania
The efficacy of intramuscular olanzapine for injection for the treatment of agitation was
established in 3 short-term (24 hours of IM treatment) placebo-controlled trials in agitated
inpatients from two diagnostic groups: schizophrenia and Bipolar I Disorder (manic or mixed
episodes). Each of the trials included a single active comparator treatment arm of either
haloperidol injection (schizophrenia studies) or lorazepam injection (bipolar mania study).
Patients enrolled in the trials needed to be: (1) judged by the clinical investigators as clinically
agitated and clinically appropriate candidates for treatment with intramuscular medication, and
(2) exhibiting a level of agitation that met or exceeded a threshold score of ≥14 on the five items
comprising the Positive and Negative Syndrome Scale (PANSS) Excited Component (i.e., poor
impulse control, tension, hostility, uncooperativeness and excitement items) with at least
one individual item score ≥4 using a 1-7 scoring system (1=absent, 4=moderate, 7=extreme). In
the studies, the mean baseline PANSS Excited Component score was 18.4, with scores ranging
from 13 to 32 (out of a maximum score of 35), thus suggesting predominantly moderate levels of
agitation with some patients experiencing mild or severe levels of agitation. The primary efficacy
measure used for assessing agitation signs and symptoms in these trials was the change from
baseline in the PANSS Excited Compo
本文档为【ZYPREXA (Olanzapine) Tablets】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。